Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875128 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
A Phase 2 study of Metastatic Breast Cancer in the Liver, sponsored by Delcath Systems.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 2
- Study locations
NCT06875128 is a Phase 2 study of Metastatic Breast Cancer in the Liver that is actively recruiting participants, run by Delcath Systems. The registered enrollment target is 90 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06875128, a Phase 2 study of Metastatic Breast Cancer in the Liver, is actively recruiting participants, sponsored by Delcath Systems.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone. Participants will: * Undergo up to two cycles of liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treatment alone * Visit clinic at least every two weeks for checkups and tests * Complete scans approximately every 8 weeks
Conditions Studied
Interventions
- DRUG Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- DRUG Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Ohio
- Ohio State University, Stefanie Spielman Comprehensive Breast Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2029-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06875128
The ClinicalTrials.gov registry entry for NCT06875128 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delcath Systems, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer in the Liver appearing as the primary indexed condition, and to 2 interventions - of which Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) is the first listed.
NCT06875128 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06875128 about?
NCT06875128 is a clinical study titled "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease". The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy wi...
What is the current status of trial NCT06875128?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-29. Estimated completion is 2029-08.
What conditions does trial NCT06875128 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer in the Liver.
What interventions are being tested in trial NCT06875128?
The interventions under investigation include: Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) (DRUG), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) (DRUG).
Who is sponsoring clinical trial NCT06875128?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875128 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.